These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 20021294)

  • 1. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.
    Darreh-Shori T; Jelic V
    Expert Opin Drug Saf; 2010 Jan; 9(1):167-76. PubMed ID: 20021294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
    Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
    Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivastigmine in Parkinson's disease dementia.
    Lalli S; Albanese A
    Expert Rev Neurother; 2008 Aug; 8(8):1181-8. PubMed ID: 18671661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
    Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R
    Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivastigmine for dementia associated with Parkinson's disease.
    Emre M; Aarsland D; Albanese A; Byrne EJ; Deuschl G; De Deyn PP; Durif F; Kulisevsky J; van Laar T; Lees A; Poewe W; Robillard A; Rosa MM; Wolters E; Quarg P; Tekin S; Lane R
    N Engl J Med; 2004 Dec; 351(24):2509-18. PubMed ID: 15590953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia.
    Cummings J; Winblad B
    Expert Rev Neurother; 2007 Nov; 7(11):1457-63. PubMed ID: 17997695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions.
    Pregelj P
    Psychogeriatrics; 2012 Sep; 12(3):165-71. PubMed ID: 22994614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials.
    Sadowsky CH; Farlow MR; Meng X; Olin JT
    Int J Clin Pract; 2010 Jan; 64(2):188-93. PubMed ID: 20089009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic rationale for the rivastigmine patch.
    Cummings J; Lefèvre G; Small G; Appel-Dingemanse S
    Neurology; 2007 Jul; 69(4 Suppl 1):S10-3. PubMed ID: 17646618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia].
    Schmidt R; Alf C; Bancher C; Benke T; Berek K; Dal-Bianco P; Führwürth G; Imarhiagbe D; Jagsch C; Lechner A; Rainer M; Reisecker F; Rotaru J; Uranüs M; Walter A; Winkler A; Wuschitz A
    Neuropsychiatr; 2009; 23(1):58-63. PubMed ID: 19272293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias.
    Ballard C; Lane R; Barone P; Ferrara R; Tekin S
    Int J Clin Pract; 2006 Jun; 60(6):639-45. PubMed ID: 16805745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease.
    Grossberg GT; Sadowsky C; Olin JT
    Int J Clin Pract; 2010 Apr; 64(5):651-60. PubMed ID: 20102418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
    Articus K; Baier M; Tracik F; Kühn F; Preuss UW; Kurz A
    Int J Clin Pract; 2011 Jul; 65(7):790-6. PubMed ID: 21645184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
    Farlow MR; Alva G; Meng X; Olin JT
    Curr Med Res Opin; 2010 Feb; 26(2):263-9. PubMed ID: 19929593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivastigmine in Parkinson's disease dementia.
    Chitnis S; Rao J
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):941-55. PubMed ID: 19619073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivastigmine for Alzheimer's disease.
    Birks J; Grimley Evans J; Iakovidou V; Tsolaki M; Holt FE
    Cochrane Database Syst Rev; 2009 Apr; (2):CD001191. PubMed ID: 19370562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivastigmine exposure provided by a transdermal patch versus capsules.
    Mercier F; Lefèvre G; Huang HL; Schmidli H; Amzal B; Appel-Dingemanse S
    Curr Med Res Opin; 2007 Dec; 23(12):3199-204. PubMed ID: 18001519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
    Poewe W; Wolters E; Emre M; Onofrj M; Hsu C; Tekin S; Lane R;
    Mov Disord; 2006 Apr; 21(4):456-61. PubMed ID: 16229010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivastigmine: new indication. Dementia and Parkinson's disease: no thank you!
    Prescrire Int; 2007 Apr; 16(88):66. PubMed ID: 17458048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.
    Burn D; Emre M; McKeith I; De Deyn PP; Aarsland D; Hsu C; Lane R
    Mov Disord; 2006 Nov; 21(11):1899-907. PubMed ID: 16960863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.